CHO Cell Doubling Time and Growth Curve: Number-Increase, Size-Increase, Stationary & Death Phases

The Four CHO Growth Phases

The CHO cell growth curve is usually drawn as the classic three-phase sigmoid — exponential, stationary, death — but a more accurate description has four phases. Pan et al. (2017), working with industrial fed-batch data, showed that between the exponential (number-increase, NI) and stationary phases, CHO cells enter a distinct size-increase (SI) phase. During SI, viable cell density (VCD) plateaus but volume and dry weight per cell climb roughly three-fold. Most of the monoclonal antibody titer in a typical 14-day fed-batch is produced during this SI phase, not the NI phase.

This article walks through all four CHO growth phases with the biology that drives them, the numbers you should expect, and the decision each phase demands from the bioprocess engineer.

Number-Increase (NI) Phase — Exponential Growth

The CHO number-increase phase is the classical exponential growth phase. VCD rises from seeding density (0.3–0.6 × 10⁶ cells/mL) to 15–25 × 10⁶ cells/mL over 5–7 days in a standard fed-batch. Cell volume stays constant around 2,000–2,500 fL per cell for CHO-K1 suspension cultures. The specific growth rate μ is close to μ_max — typically 0.029–0.039 h⁻¹ (t_d 18–24 h) for CHO-K1 and CHO-DG44, a little faster (~0.04–0.05 h⁻¹) for engineered high-productivity lines.

What's happening under the surface in NI:

• Glycolysis-dominant metabolism. Glucose uptake is fast; lactate is produced aerobically (the Warburg-like effect). Lactate rises from ~0 to 2–4 g/L.
• High mAb secretion machinery demand. ER and Golgi capacity is being built in parallel with biomass.
• qP is modest. Specific productivity per cell is 15–30 pg/cell/day for standard lines — later phases are more productive.
• IVCD accumulates linearly because VCD is still rising; daily IVCD increment grows each day.

CHO Cell Doubling Time by Sub-Line and Condition

CHO cell doubling time in suspension culture is typically 18–24 hours during the exponential (number-increase) phase. The exact value depends on the sub-line, the medium, the vessel, and whether the process is batch, fed-batch, or perfusion. Here are the practical ranges most bioprocess teams actually see at the bench and at scale.

Typical CHO doubling time by sub-line

Values reflect typical published bioprocess literature and deployment patterns. Clone-to-clone variation within a sub-line is often larger than between sub-lines — a GS-CHO clone from one lab can differ materially from one in another lab.

How to calculate CHO doubling time from VCD data

From two time points during exponential growth:

For more than two time points — the usual case in practice — fit an exponential model ln(VCD) = ln(VCD0) + μ·t and compute td = ln(2) / μ. The Growth Curve Fitter tool does this automatically from pasted time-series data and also fits logistic and Gompertz models when the simple exponential does not capture the plateau.

How CHO doubling time compares to other cell lines

Ordered fastest to slowest, typical suspension or adherent doubling times at standard culture temperature:

• Hybridoma suspension: 14–18 h — the fastest mammalian production host.
• Sf9 insect suspension: 18–22 h — for baculovirus expression and AAV.
• CHO suspension (all sub-lines): 16–24 h — discussed in detail above.
• HEK293 suspension: 20–28 h — slightly slower than CHO; used for viral vector production.
• HEK293T adherent: 24–30 h — the adherent format adds a few hours.
• Vero adherent: 24–30 h — vaccine and viral vector platform.
• Primary T cells (CAR-T): 24–48 h — patient-derived, high variability.

For a complete ordered reference (including microbial hosts that are 10–40× faster), see the doubling time reference table. For the calculation theory and how μ links doubling time to productivity, see specific growth rate (μ) formula.

Expected doubling times by process stage

CHO doubling time is not a single number — it changes systematically through the growth curve:

• Thaw / early seed train (N-4, shake flask): 22–28 h, slightly longer due to post-thaw recovery.
• Mid / late seed train (N-2, N-1): 18–22 h consistently across scales — a systematic slowdown here signals a process health issue (shear, DO, medium).
• Early fed-batch (day 0–3): 18–22 h, inoculated cells at peak μ.
• Mid fed-batch (day 3–5, near peak VCD): rising past 24 h as cells transition toward the size-increase phase.
• After 37 °C → 32 °C temperature shift: 30–40 h or effectively no division, with q_P rising 1.5–2×.
• Stationary and death phases: no division; reporting doubling time becomes meaningless.

Size-Increase (SI) Phase — Where Titer Accrues

The size-increase (SI) phase is the hidden middle phase of the CHO growth curve. Pan et al. (2017) showed that between the end of exponential growth and the onset of stationary, CHO cells keep growing — not in number but in size. Mean cell volume rises approximately linearly with time, reaching ~6,000–8,000 fL per cell by day 8–10, roughly three-fold the NI baseline. Dry weight per cell follows the same pattern.

Metabolically, the SI phase is a shift from glycolysis to TCA-dominant flux. Coulet et al. (2022) profiled this transition in detail: specific glucose uptake drops, lactate stops accumulating and starts being consumed (the CHO lactate shift), TCA-cycle intermediates rise, and mitochondrial oxygen consumption peaks. Specific productivity q_P often increases 1.5–2× relative to NI, meaning each larger cell is making more mAb per unit time than it did when it was dividing.

For a fed-batch engineer, the SI phase is where most of the final titer is actually produced. Peak VCD on day 7 and peak titer on day 12 are connected by the SI phase in between. Harvesting too early (end of NI) gives up the SI contribution; harvesting too late (deep stationary or death) costs quality.

Stationary Phase — Productivity Without Growth

The CHO stationary phase begins when cell volume stops increasing and IVCD accumulation slows markedly. VCD is typically holding in the low-20s (× 10⁶ cells/mL) in a standard fed-batch, viability is still >90 %, glucose remains supplemented via feed, and lactate is being consumed or is at a steady low level. This phase typically spans day 9–11 before viability begins to drop.

Productivity during stationary can remain high. Donaldson et al. (2021) reviewed strategies for decoupling growth and protein production in CHO cells — temperature downshift to 31–33 °C, mild hyperosmolality, and growth-arrest engineering all extend stationary productivity. Many commercial mAb processes deliberately bank titer in this phase by holding cells arrested in G1.

Death Phase — Apoptosis and Beyond

The CHO death phase begins when the balance between survival and death tips permanently. Viability falls below ~90 %, lactate may re-accumulate as stressed cells revert to glycolysis, and host cell protein, DNA, and proteases rise in the supernatant. In standard fed-batch this is usually day 11–14.

Historically, the dominant framework for CHO cell death has been apoptosis — the canonical caspase-mediated, annexin-V-positive pathway. Much of cell-line engineering in the 2000s–2010s focused on anti-apoptotic strategies (Bcl-2, Bcl-xL overexpression; caspase-3/7 knockdown) to extend stationary phase.

But Mentlak et al. (2024) showed that industrial CHO fed-batch death is often not apoptosis. Dissecting the cell-death pathways in production-scale runs, they found that the viability decline in these cultures is dominated by parthanatos and ferroptosis — oxidative, caspase-independent death modes that standard annexin V / caspase-3 assays miss entirely. This is a significant finding for anyone using flow-cytometry viability panels to decide harvest: apparently healthy cells may be committed to non-apoptotic death that shows up hours or days later as bulk viability loss.

IVCD, q_P and Titer Prediction

Integral viable cell density (IVCD) is the single most useful summary number for CHO fed-batch. Defined as the time-integral of VCD:

IVCD(t) = ∫₀^t VCD(τ) dτ

In units of 10⁶ cell-days/mL (or 10⁹ cell-hours/L), IVCD tracks the cumulative "cell-time" available for production. Because specific productivity q_P (pg/cell/day) is roughly constant over the run in many CHO processes, final titer is approximated by:

Titer ≈ q_P × IVCD

Bioprocess Decisions by CHO Growth Phase

Pulling it together, here is the practical decision framework most CHO fed-batch teams use:

• NI phase (Day 0–5): start bolus or continuous feed by day 3–4. Track glucose (keep 2–6 g/L), monitor acidification. Don't harvest.
• SI phase (Day 5–9): confirm lactate shift has occurred (metabolism turning from glycolysis to TCA-dominant); this is the productive window. Temperature downshift to 31–33 °C, if used in your process, is typically applied at the NI→SI transition.
• Stationary (Day 9–11): monitor daily IVCD increment. When ΔIVCD < 5–7 % of peak daily IVCD, further culture time is rarely worth the quality risk.
• Death (Day 11–14+): harvest. Triggers are viability < 75–80 %, lactate re-accumulation above 3–4 g/L after shift, or ≥ 3 consecutive days of post-peak VCD decline.

For the full monitoring toolkit that tells you which phase you're in, see cell growth monitoring in suspension culture. For day-by-day CHO process troubleshooting, see the CHO troubleshooting guide.

Frequently Asked Questions

What is the doubling time of CHO cells?

CHO cell doubling time is typically 18–24 h in suspension culture with chemically defined media (μ ≈ 0.029–0.039 h⁻¹). Optimised CHO-K1 or CHO-DG44 sub-lines in fed-batch can reach 16 h doubling; engineered high-productivity clones 14–18 h. This is 20–40× slower than E. coli and shapes every process decision from seed-train duration to bioreactor run length.

What is a typical CHO cell doubling time in fed-batch?

A typical CHO doubling time in commercial fed-batch mAb manufacturing is 20–22 hours during the exponential (number-increase) phase, rising to 30+ hours as the culture enters the size-increase phase. Healthy fed-batch runs target 18–22 h at seed-train transition; cultures with doubling times over 26 h should be investigated for media, shear, or contamination issues.

Does CHO-K1 doubling time differ from CHO-DG44 or CHO-S?

Yes, but the differences are modest. CHO-K1 suspension: typically 17–22 h. CHO-DG44 (DHFR-deficient): 18–24 h, often slightly slower due to MTX selection pressure. CHO-S (Thermo): 16–20 h, bred for fast growth. Engineered production lines (GS-CHO, CHOZN, GlycoExpress): 14–20 h depending on the clone. Clone-to-clone variation within a sub-line is often larger than the sub-line difference itself.

How does CHO doubling time compare to other mammalian cells?

CHO cells are among the faster-growing mammalian suspension lines. Typical comparators: HEK293 suspension 20–28 h, HEK293T adherent 24–30 h, Sf9 insect 18–22 h, Vero 24–30 h, hybridomas 14–18 h (fastest mammalian). Microbial hosts are an order of magnitude faster: E. coli 20–30 min, Pichia 1–3 h. See the doubling time reference table for a complete list.

How does temperature shift (37 °C → 32 °C) affect CHO doubling time?

Dropping the temperature from 37 °C to 32 °C in late log / early SI phase — a common fed-batch tactic — slows CHO doubling time to 30–40 h or essentially stops division. This trades biomass for specific productivity: q_P typically rises 1.5–2× while μ drops toward zero. Most commercial mAb processes use temperature shift on day 4–6 to extend culture longevity and maximise IVCD.

What doubling time should I expect in seed train?

Seed train doubling times should be consistent at 18–22 h for CHO-K1 and CHO-DG44 across scales (shake flask, spinner, rocker, stirred-tank bench). A systematic slowdown from N-4 to N-1 is a process-health signal — usually shear (small vessels), DO limitation (larger vessels), or medium-batch variability. Target within ±10 % consistency across the seed train to avoid inoculation-quality problems in the production vessel.

How do I calculate CHO doubling time from VCD data?

From two time points during exponential growth: td = (t2 − t1) × ln(2) / ln(VCD2 / VCD1). For a full growth curve, fit an exponential model ln(VCD) = ln(VCD0) + μ·t and compute td = ln(2) / μ. The Growth Curve Fitter tool automates both approaches.

What are the growth phases of CHO cells?

CHO cells in fed-batch culture pass through four phases: the number-increase (NI) or exponential phase where VCD doubles every 18–24 h; the size-increase (SI) phase where VCD plateaus but cell volume rises ~3×; the stationary phase where productivity continues but growth stops; and the death phase where viability drops and proteolysis accelerates.

What is the lactate shift in CHO fed-batch?

The lactate shift is the metabolic switch where CHO cells stop producing lactate (glycolysis-dominant) and start consuming it (TCA-dominant). It usually coincides with the NI→SI transition and precedes peak titer by 1–3 days. Re-accumulation of lactate after the shift is an early stress signal.

What is IVCD and why does it matter?

IVCD (integral viable cell density) is the time-integral of VCD, in 10⁶ cell-days/mL. Because q_P is roughly constant over the run, final titer ≈ q_P × IVCD. IVCD predicts titer better than peak VCD alone because it captures how long cells were productive.

When do CHO cells enter the size-increase phase?

Around day 5–7 in a typical 14-day fed-batch, when the NI phase ends. Pan et al. (2017) characterised this phase quantitatively: volume and dry weight per cell rise ~3× linearly with time, lactate consumption begins, and TCA flux increases while glycolytic flux drops.

References

1. Pan X, Dalm C, Wijffels RH, Martens DE. Metabolic characterization of a CHO cell size increase phase in fed-batch cultures. Applied Microbiology and Biotechnology (2017). DOI: 10.1007/s00253-017-8531-y.
2. Coulet M, Kepp O, Kroemer G, Basmaciogullari S. Metabolic Profiling of CHO Cells during the Production of Biotherapeutics. Cells (2022) 11(12):1929. DOI: 10.3390/cells11121929.
3. Donaldson JS, Dale MP, Rosser SJ. Decoupling Growth and Protein Production in CHO Cells: A Targeted Approach. Frontiers in Bioengineering and Biotechnology (2021) 9:658325. DOI: 10.3389/fbioe.2021.658325.
4. Mentlak DA, Raven J, Moses T, Pybus LP, Dickman MJ, Smales CM. Dissecting cell death pathways in fed-batch bioreactors. Biotechnology Journal (2024). DOI: 10.1002/biot.202300257.
5. Metze S, Ruhl S, Greller G, Grimm C, Scholz J. Monitoring online biomass with a capacitance sensor during scale-up of industrially relevant CHO cell culture fed-batch processes in single-use bioreactors. Bioprocess and Biosystems Engineering (2020). DOI: 10.1007/s00449-019-02216-4.